Search Results
May 13, 2026, 08:39 ET Cantex and Headlamp Health Forge Strategic Partnership to Accelerate Azeliragon Development via Agentic Precision Neuropsychiatry for Severe Depression and Fatigue in Patients with Multiple Sclerosis
outperforms general-purpose models in clinical comprehensiveness and epistemic calibration. Our vertically integrated intelligence stack de-risks R&D by identifying multifactorial biomarker signatures and responder-rich phenotypes, while simultaneously providing clinicians with real-time, precision
More news about: Headlamp Health
May 13, 2026, 08:31 ET Sales Xceleration Named to Selling Power Magazine's Top Sales Training Companies 2026 List
https://bit.ly/3R2BJwo.
More news about: Sales Xceleration
May 13, 2026, 08:30 ET K-Beauty Sunscreen Leader Kolmar Korea Expands into Scalp and Hair Sun Care
increasingly segmented, demand for scalp and hair protection solutions is growing rapidly," said a representative from Kolmar Korea. "Leveraging our R&D capabilities spanning product development, material innovation, and efficacy evaluation, we aim to lead the next-generation hair sun care market."Kolmar
More news about: Kolmar Korea
May 13, 2026, 08:30 ET K-Beauty Sunscreen Leader Kolmar Korea Expands into Scalp and Hair Sun Care
increasingly segmented, demand for scalp and hair protection solutions is growing rapidly," said a representative from Kolmar Korea. "Leveraging our R&D capabilities spanning product development, material innovation, and efficacy evaluation, we aim to lead the next-generation hair sun care market."Kolmar
More news about: Kolmar Korea
May 13, 2026, 08:30 ET Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
in 2026.Financial Results for the Quarter Ended March 31, 2026Research and Development (R&D) expenses: R&D expenses for the quarter ended March 31, 2026, were $1.6 million compared to $1.3 million for the comparable period in 2025.General
More news about: Azitra, Inc.
May 13, 2026, 08:25 ET Hongli Group Inc. Reports Robust Fiscal Year 2025 Results: Revenue Grows 39% to $19.6 Million as Company Delivers $3.8 Million Profit Turnaround
the growth in sales during 2025.Research and development ("R&D") expensesSubstantially all research and development (R&D) costs reflect the Company's efforts in product development activities. In 2025, R&D expenses were approximately $1.0 million, representing an increase
More news about: Hongli Group Inc.
May 13, 2026, 08:00 ET XRDNA and University of Utah Launch Strategic R&D Partnership Built on Mission Fabric™ to Power the Next Generation of Executable Systems
partnering with the University of Utah, we're creating a living R&D environment where research, operations, and real-world deployment can function as one continuously coordinated system."The collaboration focuses on building a unified R&D operating system that integrates infrastructure, data, workflows,
More news about: XRDNA Inc
May 13, 2026, 08:00 ET QuartzBio Secures Growth Investment from Eir Partners to Accelerate Clinical Trial Intelligence
ensuring biomarker‑ready data at readout.By embedding domain‑specific AI directly into clinical and translational workflows, QuartzBio enables R&D teams to move faster and with greater confidence—without increasing operational risk or administrative burden.Focused Investment in Product
More news about: QuartzBio
May 13, 2026, 08:00 ET PagBank reports recurring net income of R$ 575 million in 1Q26, driven by revenue growth and efficiency gains
content:https://www.prnewswire.co.uk/news-releases/pagbank-reports-recurring-net-income-of-r-575-million-in-1q26-driven-by-revenue-growth-and-efficiency-gains-302770126.html
More news about: PagBank
May 13, 2026, 08:00 ET PagBank reports recurring net income of R$ 575 million in 1Q26, driven by revenue growth and efficiency gains
multimedia:https://www.prnewswire.com/news-releases/pagbank-reports-recurring-net-income-of-r-575-million-in-1q26-driven-by-revenue-growth-and-efficiency-gains-302770125.htmlSOURCE
More news about: PagBank
May 13, 2026, 08:00 ET PagBank registra utilidad neta de R$ 575 millones en el 1T26, impulsada por la expansión de ingresos y ganancias de eficiencia
content:https://www.prnewswire.com/news-releases/pagbank-registra-utilidad-neta-de-r-575-millones-en-el-1t26-impulsada-por-la-expansion-de-ingresos-y-ganancias-de-eficiencia-302770134.html
More news about: PagBank
May 13, 2026, 08:00 ET PagBank registra utilidad neta de R$ 575 millones en el 1T26, impulsada por la expansión de ingresos y ganancias de eficiencia
multimedia:https://www.prnewswire.com/mx/comunicados-de-prensa/pagbank-registra-utilidad-neta-de-r-575-millones-en-el-1t26-impulsada-por-la-expansion-de-ingresos-y-ganancias-de-eficiencia-302770131.htmlFUENTE
More news about: PagBank
May 13, 2026, 08:00 ET PagBank annonce un bénéfice net récurrent de 575 millions de R$ au 1er trimestre 26, grâce à la croissance des recettes et à des gains d'efficacité
content:https://www.prnewswire.com/news-releases/pagbank-annonce-un-benefice-net-recurrent-de-575-millions-de-r-au-1er-trimestre-26-grace-a-la-croissance-des-recettes-et-a-des-gains-defficacite-302770858.html
More news about: PagBank
May 13, 2026, 08:00 ET Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
marketable securities are expected to allow TYRA to execute on its plans into the second half of 2028.Research and Development (R&D) Expenses. R&D expenses for the three months ended March 31, 2026 were $33.5 million compared to $25.0 million for the same period in 2025. The increase
More news about: Tyra Biosciences
May 13, 2026, 07:31 ET Bioretec clarifies its 2026-2028 financial target regarding the sales margin
https://news.cision.com/bioretec/r/bioretec-clarifies-its-2026-2028-financial-target-regarding-the-sales-margin,c4348396
More news about: Bioretec
May 13, 2026, 07:30 ET Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
best-in-class MC4R agonists. To support this, we have made significant advancements in improving MC4R selectivity and reducing MC1R activity, resulting in highly selective MC4R lead candidates," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin Technologies. "Our once-weekly MC4R selective
More news about: Palatin Technologies, Inc.
May 13, 2026, 07:28 ET Bioretec clarifies its 2026-2028 financial target regarding the sales margin
https://news.cision.com/bioretec/r/bioretec-clarifies-its-2026-2028-financial-target-regarding-the-sales-margin,c4348396
More news about: Bioretec
May 13, 2026, 07:05 ET Dotmatics introduces Luma Agent: the AI co-scientist built on structured scientific data
https://www.dotmatics.com/luma/artificial-intelligence.About DotmaticsDotmatics is a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists' favorite applications drive efficiency and accelerate innovation. More than 2
More news about: Dotmatics Inc
May 13, 2026, 07:04 ET Invitation to Minesto's webinar: Q1 update by CEO
https://news.cision.com/minesto-ab/r/invitation-to-minesto-s-webinar--q1-update-by-ceo,c4348351
More news about: Minesto AB
May 13, 2026, 07:01 ET Invitation to Minesto's webinar: Q1 update by CEO
https://news.cision.com/minesto-ab/r/invitation-to-minesto-s-webinar--q1-update-by-ceo,c4348351
More news about: Minesto AB
May 13, 2026, 07:00 ET Oishii Announces First Closing of $150M in Series C Financing as It Scales Its Indoor Smart Farm™ Model
states, launched in Toronto as its first international retail market, introduced new retail formats and product offerings, and is now advancing its R&D capabilities in Japan through the development of its first-of-its-kind Open Innovation Center in Tokyo.Robotics and automation have become central
More news about: Oishii
May 13, 2026, 06:50 ET Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
partnershipsAdvance PRX–115 as a potential best–in–class therapy for patients with uncontrolled goutAdvance rare renal programs leveraging the Company's R&D strengthsThe Company reaffirms its previously stated 2026 revenue expectations: Total revenue in 2026 to range
More news about: Protalix BioTherapeutics, Inc.
May 13, 2026, 06:44 ET Changan Group Unveils "Vast Ocean Plan 2.0" with Middle East & Africa Named a Priority Region
user trustPartnerships: Deeper collaboration across technology, manufacturing, and market developmentInvestment: Greater focus on R&D, brand building, and ecosystem developmentService: Faster after-sales response times and stronger local support networksTeams: More
More news about: Changan Group
May 13, 2026, 06:30 ET Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
partnering options with interested parties.Financial and Operating ResultsResearch and Development (R&D) Expenses were $25.6 million for the three months ended March 31, 2026, as compared to $21.5 million for the three months ended March 31, 2025.
More news about: Immunic, Inc.
May 13, 2026, 06:18 ET T-Global Technology Partners with France's SiPearl to Advance Next-Generation HPC Cooling Technologies
management has become a critical factor in enabling higher computing performance, energy efficiency, and system reliability. Under this two-year joint R&D initiative, T-Global will collaborate with SiPearl, the European fabless designer of high-performance, energy-efficient CPUs for HPC, AI, and
More news about: T-Global Technology